** Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 3.4% to $7.54
** NTLA reports Q1 net loss of $1.10 per share, narrower than the net loss of $1.12 a year ago
** Posts Q1 collaboration revenue of $16.63 million, compared with $28.9 million a year ago
** Co says it has cash and cash equivalents of $707.1 million as of March 31, with runway expected into H1 2027
** Including session's moves, stock down 35.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。